A multicentre study of amphotericin B treatment for histoplasmosis: assessing mortality rates and adverse events.
William Kazunori SekiguchiVítor Falcão de OliveiraFrancelise Bridi CavassinMariane TabordaAdriana Satie Gonçalves Kono MagriIsabela Carvalho Leme Vieira da CruzJose Ernesto VidalDiego Rodrigues FalciCássia Silva de Miranda GodoyRenata de Bastos Ascenço SoaresCarla Sakuma de OliveiraAna Verena Almeida MendesGiovanni Luís BredaCaroline Martins RegoMaíra Araujo FélixPaula Pacheco KatopodisJulia Raquel da Silva do ÓMirela Pereira Lima AbrãoJoão Luiz Baú-CarneiroTalita Teles Teixeira PereiraFlávio Queiroz-TellesMarcello Mihailenko Chaves MagriPublished in: The Journal of antimicrobial chemotherapy (2024)
We found that D-AmB was the main formulation, which was also associated with a higher mortality rate. Lipid formulations of AmB have become more readily available in the public health system in Brazil. Further studies to evaluate the effectiveness of L-AmB will likely show improvements in the treatment outcomes for patients with disseminated histoplasmosis.